comprehensive -WSS

comprehensive

author：fashion 2025-09-06 01:58:43 - browse：32693

Gilead office remdesivir — Yichuan Cao/Sipa USA

Gilead Sciences said Monday it will acquire CymaBay Therapeutics for $4.3 billion, adding a new treatment for a liver disease that is on track for approval later this year.

The deal values CymaBay at $32.50 per share, 27% higher than the stock’s close last Friday. That’s a relatively small takeout premium, but CymaBay shares have doubled in value since last fall on growing investor confidence in the company’s lead drug and speculation that the company could be acquired.

CymaBay’s drug, called seladelpar, is being developed for the treatment of primary biliary cholangitis, or PBC, a type of liver disease mainly affecting women that causes decreased liver function, and debilitating itching and fatigue. Progression of PBC to more advanced stages increases the risk of liver-related death.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

explore

WSS

IVF doctors demand details after CooperSurgical lawsuit

Some medical students still think black patients feel less pain

$1 billion proposal to grow Boston, Massachusetts biotech

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

Why Talkspace is targeting Medicare, a tricky market

First over

leisure time

comprehensive

leisure time

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

State of the Union pitch: Bigger Medicare drug price negotiations

Sports medicine is finally prioritizing gender equality

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

Medicare proposal to cover medical devices draws a mixed reaction

IVF doctors demand details after CooperSurgical lawsuit

23andMe had bad news about my health. I wish a person had delivered it

Why we need mandatory labeling of GMO products

Alkermes shareholders re

Biden's 'march

explore

Unmasking the 'centricity' illusion in clinical trials

Some medical students still think black patients feel less pain

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Guardant Health colon cancer test endorsed by FDA advisory panel

Guardant Health colon cancer test endorsed by FDA advisory panel

Achieving telehealth equity for people with hearing loss

hotspot

explore

explore

Wikipedia